Disorders of Glycoprotein Metabolism

Introduction to Disorders of Glycoprotein Metabolism

Disorders of glycoprotein metabolism encompass a diverse group of genetic conditions that affect the synthesis, processing, or degradation of glycoproteins. These disorders can impact multiple organ systems and often present with a wide range of clinical manifestations.

Key points:

  • Glycoproteins are proteins with attached carbohydrate chains (glycans)
  • These disorders can affect either the synthesis (e.g., CDG) or degradation (e.g., oligosaccharidoses) of glycoproteins
  • Most are inherited in an autosomal recessive manner
  • Clinical presentations can vary widely, from severe multisystem disorders to milder, later-onset forms
  • Diagnosis often requires specialized biochemical and genetic testing

Congenital Disorders of Glycosylation (CDG)

CDG are a group of disorders affecting the synthesis and processing of glycans attached to proteins or lipids.

Classification:

  • Type I CDG: Defects in glycan assembly
  • Type II CDG: Defects in glycan processing

Clinical Features:

  • Developmental delay and intellectual disability
  • Hypotonia
  • Failure to thrive
  • Seizures
  • Liver dysfunction
  • Coagulation abnormalities
  • Dysmorphic features
  • Skeletal abnormalities
  • Retinopathy

Diagnosis:

  • Transferrin isoelectric focusing (most common screening test)
  • Apolipoprotein C-III isoelectric focusing
  • Genetic testing
  • Enzyme assays in some cases

Examples:

  • PMM2-CDG (formerly CDG-Ia)
  • MPI-CDG (formerly CDG-Ib)
  • ALG3-CDG
  • COG7-CDG

Mucolipidoses

Mucolipidoses are disorders that combine features of both mucopolysaccharidoses and sphingolipidoses. They are characterized by defects in the trafficking of lysosomal enzymes.

Types:

  • Mucolipidosis II (I-cell disease)
  • Mucolipidosis III (Pseudo-Hurler polydystrophy)
  • Mucolipidosis IV

Clinical Features:

  • Coarse facial features
  • Skeletal abnormalities
  • Developmental delay
  • Organomegaly
  • Corneal clouding

Diagnosis:

  • Elevated serum lysosomal enzymes
  • Genetic testing
  • Enzyme assays in cultured fibroblasts

Specific Features:

Mucolipidosis II (I-cell disease): Most severe form, presents in infancy

Mucolipidosis III: Milder form with later onset

Mucolipidosis IV: Characterized by severe neurological impairment and eye abnormalities

Oligosaccharidoses

Oligosaccharidoses are disorders of glycoprotein catabolism, resulting in the accumulation of oligosaccharides in lysosomes.

Types:

  • α-Mannosidosis
  • β-Mannosidosis
  • Fucosidosis
  • Aspartylglucosaminuria
  • Schindler disease/Kanzaki disease

General Clinical Features:

  • Progressive intellectual disability
  • Coarse facial features
  • Skeletal abnormalities
  • Hearing loss
  • Hepatosplenomegaly

Diagnosis:

  • Urine oligosaccharide analysis
  • Enzyme assays in leukocytes or fibroblasts
  • Genetic testing

Specific Features:

α-Mannosidosis: Immunodeficiency, hearing loss, intellectual disability

Fucosidosis: Angiokeratomas, visceromegaly, neurological deterioration

Aspartylglucosaminuria: Predominantly affects individuals of Finnish descent

Sialidoses

Sialidoses are lysosomal storage disorders caused by deficiency of neuraminidase (sialidase).

Types:

  • Type I (Cherry-red spot myoclonus syndrome)
  • Type II (Mucolipidosis I)

Clinical Features:

  • Cherry-red spot in the macula
  • Progressive visual loss
  • Myoclonus
  • Ataxia
  • Seizures

Specific Features:

Type I: Later onset, milder course, primarily neurological symptoms

Type II: Earlier onset, more severe, with dysmorphic features and organomegaly

Diagnosis:

  • Urine oligosaccharide analysis
  • Enzyme assay for neuraminidase
  • Genetic testing of NEU1 gene

Diagnosis of Disorders of Glycoprotein Metabolism

Diagnosis of these disorders often requires a combination of clinical, biochemical, and genetic approaches:

Clinical Evaluation:

  • Detailed medical history
  • Physical examination
  • Developmental assessment

Biochemical Testing:

  • Urine oligosaccharide analysis
  • Serum transferrin isoelectric focusing (for CDG)
  • Enzyme assays in leukocytes, fibroblasts, or dried blood spots

Genetic Testing:

  • Next-generation sequencing panels
  • Whole exome or whole genome sequencing

Other Investigations:

  • Neuroimaging (MRI, CT)
  • Ophthalmological examination
  • Skeletal surveys
  • Tissue biopsies in some cases

Early diagnosis is crucial for appropriate management and genetic counseling. However, the rarity and heterogeneity of these disorders can make diagnosis challenging.

Treatment of Disorders of Glycoprotein Metabolism

Treatment approaches vary depending on the specific disorder and often involve multidisciplinary care:

General Approaches:

  • Supportive care
  • Management of symptoms and complications
  • Physical, occupational, and speech therapy
  • Nutritional support

Specific Therapies:

  • Enzyme Replacement Therapy (ERT): Available for some disorders (e.g., α-mannosidosis)
  • Substrate Reduction Therapy: Under investigation for some conditions
  • Bone Marrow Transplantation: Considered in select cases
  • Gene Therapy: Experimental approach in research phase

Management of Complications:

  • Anticonvulsants for seizure control
  • Cardiac management
  • Orthopedic interventions
  • Ophthalmological care

Emerging Therapies:

  • Chaperone therapy
  • Antisense oligonucleotides
  • Small molecule approaches

Treatment is typically lifelong and requires regular monitoring and adjustment. The development of new therapies is an active area of research for many of these rare disorders.



Disorders of Glycoprotein Metabolism
  1. What is the primary function of glycoproteins in the human body?
    Glycoproteins play crucial roles in cell recognition, signaling, and structural support.
  2. Which enzyme deficiency is responsible for aspartylglucosaminuria?
    Aspartylglucosaminidase deficiency
  3. What is the inheritance pattern of most glycoprotein metabolism disorders?
    Autosomal recessive
  4. In Fucosidosis, which enzyme is deficient?
    Alpha-L-fucosidase
  5. What is the main storage material in I-cell disease?
    Glycoproteins and glycolipids
  6. Which organelle is primarily affected in most glycoprotein metabolism disorders?
    Lysosomes
  7. What is the alternative name for Sialidosis Type I?
    Cherry-red spot myoclonus syndrome
  8. In which disorder is there a deficiency of beta-mannosidase?
    Beta-mannosidosis
  9. What is the primary clinical feature of Schindler disease?
    Neurodegeneration
  10. Which glycoprotein metabolism disorder is characterized by coarse facial features and hepatosplenomegaly?
    Mucolipidosis III (Pseudo-Hurler polydystrophy)
  11. What is the enzyme deficiency in alpha-mannosidosis?
    Alpha-mannosidase
  12. Which diagnostic test is commonly used to screen for glycoprotein metabolism disorders?
    Urine oligosaccharide analysis
  13. What is the primary treatment approach for most glycoprotein metabolism disorders?
    Supportive care and symptom management
  14. In which disorder is there accumulation of sialic acid-containing compounds?
    Sialidosis
  15. What is the typical age of onset for infantile free sialic acid storage disease?
    Birth to early infancy
  16. Which glycoprotein metabolism disorder is associated with skeletal dysplasia and corneal clouding?
    Mucolipidosis IV
  17. What is the primary storage material in Schindler disease?
    Glycopeptides and oligosaccharides
  18. Which enzyme is deficient in Galactosialidosis?
    Cathepsin A (Protective protein)
  19. What is the characteristic feature of I-cell disease on electron microscopy?
    Inclusion bodies in fibroblasts
  20. Which glycoprotein metabolism disorder is associated with a cherry-red spot in the macula?
    Sialidosis
  21. What is the main biochemical abnormality in Fucosidosis?
    Accumulation of fucose-containing glycolipids and glycoproteins
  22. Which organ systems are commonly affected in glycoprotein metabolism disorders?
    Central nervous system, skeletal system, and visceral organs
  23. What is the primary diagnostic method for confirming a specific glycoprotein metabolism disorder?
    Enzyme activity assay in leukocytes or cultured fibroblasts
  24. Which glycoprotein metabolism disorder is associated with angiokeratoma corporis diffusum?
    Fucosidosis
  25. What is the genetic basis of most glycoprotein metabolism disorders?
    Mutations in genes encoding lysosomal enzymes or transport proteins
  26. Which imaging technique is commonly used to assess brain involvement in glycoprotein metabolism disorders?
    Magnetic Resonance Imaging (MRI)
  27. What is the primary storage material in alpha-mannosidosis?
    Mannose-rich oligosaccharides
  28. Which glycoprotein metabolism disorder is characterized by the presence of vacuolated lymphocytes?
    Sialidosis
  29. What is the typical life expectancy for severe forms of glycoprotein metabolism disorders?
    Often reduced, with many patients not surviving beyond childhood or early adulthood
  30. Which therapeutic approach shows promise for some glycoprotein metabolism disorders but is still under investigation?
    Enzyme replacement therapy
Mucolipidoses
  1. What is the primary characteristic of mucolipidoses?
    Combined storage of mucopolysaccharides and lipids
  2. How many types of mucolipidoses are currently recognized?
    Four main types (I, II, III, and IV)
  3. Which mucolipidosis is also known as sialidosis?
    Mucolipidosis I
  4. What is the alternative name for Mucolipidosis II?
    I-cell disease
  5. Which enzyme is deficient in Mucolipidosis III?
    N-acetylglucosamine-1-phosphotransferase
  6. What is the inheritance pattern of mucolipidoses?
    Autosomal recessive
  7. Which mucolipidosis is characterized by psychomotor retardation and corneal clouding?
    Mucolipidosis IV
  8. What is the primary cellular defect in I-cell disease (Mucolipidosis II)?
    Missorting of lysosomal enzymes
  9. Which gene is mutated in Mucolipidosis IV?
    MCOLN1 (Mucolipin-1)
  10. What is the typical age of onset for Mucolipidosis II?
    Birth or early infancy
  11. Which mucolipidosis is also known as pseudo-Hurler polydystrophy?
    Mucolipidosis III
  12. What is the primary biochemical defect in Mucolipidosis II and III?
    Defective phosphorylation of lysosomal enzymes
  13. Which diagnostic test is used to confirm Mucolipidosis II?
    Elevated lysosomal enzyme activity in serum
  14. What is the primary storage material in Mucolipidosis IV?
    Gangliosides and mucopolysaccharides
  15. Which clinical feature distinguishes Mucolipidosis III from Mucolipidosis II?
    Milder symptoms and later onset
  16. What is the characteristic finding in fibroblasts of patients with I-cell disease?
    Inclusion bodies (I-cells)
  17. Which organ systems are commonly affected in Mucolipidosis II?
    Skeletal, cardiovascular, and central nervous systems
  18. What is the life expectancy for patients with Mucolipidosis II?
    Usually less than 10 years
  19. Which imaging technique is commonly used to assess bone abnormalities in mucolipidoses?
    X-ray radiography
  20. What is the primary treatment approach for mucolipidoses?
    Supportive care and symptom management
  21. Which mucolipidosis is associated with a defect in the GNPTAB gene?
    Mucolipidosis II and III
  22. What is the characteristic eye finding in Mucolipidosis IV?
    Corneal clouding
  23. Which mucolipidosis is characterized by the least severe clinical presentation?
    Mucolipidosis III
  24. What is the primary cellular compartment affected in mucolipidoses?
    Lysosomes
  25. Which diagnostic test can be performed prenatally to detect mucolipidoses?
    Enzyme activity assay in cultured amniotic fluid cells or chorionic villi
  26. What is the characteristic facial appearance in severe forms of mucolipidoses?
    Coarse facial features
  27. Which mucolipidosis is associated with achlorhydria and iron deficiency anemia?
    Mucolipidosis IV
  28. What is the primary neurological symptom in Mucolipidosis I (Sialidosis)?
    Myoclonus
  29. Which therapeutic approach is being investigated for some forms of mucolipidoses?
    Gene therapy
  30. What is the characteristic finding on electron microscopy of skin biopsies in Mucolipidosis IV?
    Cytoplasmic inclusions with concentric lamellae
Congenital Disorders of Glycosylation (CDG)
  1. What is the primary defect in Congenital Disorders of Glycosylation?
    Abnormal glycosylation of proteins and lipids
  2. How many types of CDG have been identified to date?
    Over 100 different types
  3. What is the most common type of CDG?
    PMM2-CDG (formerly known as CDG-Ia)
  4. Which enzyme is deficient in PMM2-CDG?
    Phosphomannomutase 2
  5. What is the inheritance pattern of most CDGs?
    Autosomal recessive
  6. Which diagnostic test is considered the gold standard for screening CDGs?
    Transferrin isoelectric focusing
  7. What are the two main categories of CDGs?
    Type I (defects in glycan assembly) and Type II (defects in glycan processing)
  8. Which organ systems are commonly affected in CDGs?
    Central nervous system, gastrointestinal system, and musculoskeletal system
  9. What is a characteristic clinical feature of PMM2-CDG?
    Inverted nipples and abnormal fat distribution
  10. Which type of CDG is associated with a defect in dolichol-phosphate-mannose synthase?
    DPM1-CDG
  11. What is the primary treatment approach for most CDGs?
    Supportive care and symptom management
  12. Which CDG type is associated with severe hypoglycemia and liver dysfunction?
    ALG1-CDG
  13. What is the characteristic finding on brain MRI in many CDG patients?
    Cerebellar atrophy
  14. Which CDG is associated with ichthyosis and liver cirrhosis?
    MPDU1-CDG
  15. What is the typical age of onset for most CDGs?
    Infancy or early childhood
  16. Which CDG is characterized by severe epilepsy and microcephaly?
    SRD5A3-CDG
  17. What is the primary biochemical pathway affected in most Type I CDGs?
    N-linked glycosylation
  18. Which CDG is associated with cutis laxa and skeletal dysplasia?
    ATP6V0A2-CDG
  19. What is the characteristic eye finding in many CDG patients?
    Strabismus
  20. Which CDG is associated with congenital cataracts and growth hormone deficiency?
    PMM2-CDG
  21. What is the primary laboratory finding in most Type I CDGs?
    Decreased glycosylation of serum transferrin
  22. Which CDG is characterized by severe intellectual disability and seizures?
    ALG3-CDG
  23. What is the role of dietary mannose supplementation in some CDGs?
    It can improve glycosylation in certain types, such as MPI-CDG
  24. Which CDG is associated with recurrent thrombosis and protein-losing enteropathy?
    TMEM165-CDG
  25. What is the primary diagnostic method for confirming a specific CDG type?
    Genetic testing
  26. Which CDG is characterized by hyperinsulinemic hypoglycemia and enteropathy?
    PGAP3-CDG
  27. What is the role of glycosylation in normal cellular function?
    It is crucial for protein folding, stability, and cell-cell interactions
  28. Which CDG is associated with skeletal dysplasia and retinal degeneration?
    COG1-CDG
  29. What is the primary challenge in diagnosing CDGs?
    Clinical and biochemical heterogeneity among different types
  30. Which therapeutic approach shows promise for some CDGs but is still under investigation?
    Gene therapy and enzyme replacement therapy
Oligosaccharidoses
  1. What are oligosaccharidoses?
    Lysosomal storage disorders characterized by defective breakdown of oligosaccharides
  2. Which enzyme deficiency causes alpha-mannosidosis?
    Alpha-mannosidase
  3. What is the inheritance pattern of most oligosaccharidoses?
    Autosomal recessive
  4. Which oligosaccharidosis is caused by a deficiency of beta-mannosidase?
    Beta-mannosidosis
  5. What is the primary storage material in Fucosidosis?
    Fucose-containing glycolipids and glycoproteins
  6. Which diagnostic test is commonly used to screen for oligosaccharidoses?
    Urine oligosaccharide analysis
  7. What is the enzyme deficiency in Aspartylglucosaminuria?
    Aspartylglucosaminidase
  8. Which oligosaccharidosis is characterized by angiokeratoma corporis diffusum?
    Fucosidosis
  9. What is the primary clinical feature of Schindler disease?
    Neurodegeneration
  10. Which enzyme is deficient in Pompe disease?
    Acid alpha-glucosidase (GAA)
  11. What is the characteristic facial appearance in severe forms of oligosaccharidoses?
    Coarse facial features
  12. Which oligosaccharidosis is associated with cherry-red spots in the macula?
    GM1 gangliosidosis
  13. What is the primary storage material in alpha-mannosidosis?
    Mannose-rich oligosaccharides
  14. Which organ systems are commonly affected in oligosaccharidoses?
    Central nervous system, skeletal system, and visceral organs
  15. What is the enzyme deficiency in GM1 gangliosidosis?
    Beta-galactosidase
  16. Which oligosaccharidosis is characterized by severe skeletal dysplasia?
    Sialidosis type II
  17. What is the primary treatment approach for most oligosaccharidoses?
    Supportive care and symptom management
  18. Which imaging technique is commonly used to assess brain involvement in oligosaccharidoses?
    Magnetic Resonance Imaging (MRI)
  19. What is the characteristic eye finding in many oligosaccharidoses?
    Corneal clouding
  20. Which oligosaccharidosis is associated with intellectual disability and psychiatric symptoms?
    Aspartylglucosaminuria
  21. What is the primary cellular compartment affected in oligosaccharidoses?
    Lysosomes
  22. Which diagnostic method is used to confirm a specific oligosaccharidosis?
    Enzyme activity assay in leukocytes or cultured fibroblasts
  23. What is the typical age of onset for infantile forms of oligosaccharidoses?
    Birth to early infancy
  24. Which oligosaccharidosis is characterized by the presence of vacuolated lymphocytes?
    Sialidosis
  25. What is the role of bone marrow transplantation in treating some oligosaccharidoses?
    It can provide enzyme-producing cells and slow disease progression in some cases
  26. Which oligosaccharidosis is associated with hepatosplenomegaly and cardiac involvement?
    Pompe disease
  27. What is the primary biochemical abnormality in Schindler disease?
    Accumulation of glycopeptides and oligosaccharides
  28. Which therapeutic approach is being investigated for some oligosaccharidoses?
    Enzyme replacement therapy and gene therapy
  29. What is the characteristic finding on electron microscopy of skin biopsies in oligosaccharidoses?
    Vacuoles or inclusion bodies in various cell types
  30. Which oligosaccharidosis is associated with a defect in the MANBA gene?
    Beta-mannosidosis
Sialidoses
  1. What is the primary enzyme deficiency in sialidoses?
    Neuraminidase (sialidase)
  2. How many main types of sialidoses are recognized?
    Two main types (Type I and Type II)
  3. What is the alternative name for Sialidosis Type I?
    Cherry-red spot myoclonus syndrome
  4. Which gene is mutated in sialidoses?
    NEU1 gene
  5. What is the inheritance pattern of sialidoses?
    Autosomal recessive
  6. What is the characteristic eye finding in sialidoses?
    Cherry-red spot in the macula
  7. Which type of sialidosis has a later onset and milder symptoms?
    Sialidosis Type I
  8. What is the primary neurological symptom in Sialidosis Type I?
    Myoclonus
  9. Which type of sialidosis is associated with hydrops fetalis?
    Sialidosis Type II (congenital form)
  10. What is the primary storage material in sialidoses?
    Sialic acid-containing oligosaccharides and glycopeptides
  11. Which diagnostic test is used to confirm sialidoses?
    Neuraminidase enzyme activity assay in cultured fibroblasts or leukocytes
  12. What is the typical age of onset for Sialidosis Type I?
    Second or third decade of life
  13. Which clinical feature distinguishes Sialidosis Type II from Type I?
    Presence of dysmorphic features and organomegaly
  14. What is the characteristic finding in peripheral blood smears of sialidosis patients?
    Vacuolated lymphocytes
  15. Which organ systems are commonly affected in Sialidosis Type II?
    Central nervous system, skeletal system, and visceral organs
  16. What is the primary treatment approach for sialidoses?
    Supportive care and symptom management
  17. Which imaging technique is commonly used to assess brain involvement in sialidoses?
    Magnetic Resonance Imaging (MRI)
  18. What is the life expectancy for patients with Sialidosis Type I?
    Often normal or near-normal life expectancy
  19. Which subtype of Sialidosis Type II has the earliest onset?
    Congenital or hydropic form
  20. What is the primary biochemical abnormality in urine samples of sialidosis patients?
    Increased excretion of sialyloligosaccharides
  21. Which therapeutic approach is being investigated for sialidoses?
    Enzyme replacement therapy and gene therapy
  22. What is the characteristic facial appearance in Sialidosis Type II?
    Coarse facial features
  23. Which neurological symptom is common in both types of sialidoses?
    Ataxia
  24. What is the role of genetic counseling in sialidoses?
    To inform families about the risk of recurrence and available prenatal testing options
  25. Which diagnostic technique can be used for prenatal diagnosis of sialidoses?
    Enzyme activity assay in cultured amniotic fluid cells or chorionic villi
  26. What is the primary cellular compartment affected in sialidoses?
    Lysosomes
  27. Which type of sialidosis is associated with skeletal abnormalities?
    Sialidosis Type II
  28. What is the role of neuraminidase in normal cellular function?
    It cleaves terminal sialic acid residues from glycoproteins and glycolipids
  29. Which clinical feature can help differentiate sialidoses from other lysosomal storage disorders?
    Presence of cherry-red spot without organomegaly in Type I
  30. What is the primary challenge in developing treatments for sialidoses?
    Difficulty in delivering enzyme or gene therapy across the blood-brain barrier


Further Reading
Powered by Blogger.